v3.26.1
Accounting Principles - Additional Information (Detail)
$ / shares in Units, $ in Thousands
 1 Months Ended 2 Months Ended 4 Months Ended 12 Months Ended
Nov. 17, 2025
USD ($)
May 03, 2024
USD ($)
shares
Nov. 14, 2023
USD ($)
$ / shares
shares
Nov. 06, 2023
USD ($)
shares
Nov. 01, 2023
USD ($)
Cell
$ / shares
shares
May 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
shares
May 03, 2024
USD ($)
shares
Dec. 31, 2025
USD ($)
shares
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
shares
Sep. 30, 2024
shares
May 28, 2024
shares
May 12, 2024
shares
Mar. 05, 2024
shares
Dec. 31, 2022
USD ($)
shares
Disclosure of changes in accounting estimates [line items]                                
Cash and cash equivalents             $ 136,708   $ 61,533 $ 143,251 $ 136,708         $ 93,216
Deposit                 144,800 115,800            
Proceeds from sale of ordinary shares       $ 44,900             35,700          
Number of shares issued | shares       16,000,000               238 135,980 2,120 204,334  
Proportion of ownership interest       22.00%                        
Decrease (increase) in trade receivables and other current assets                 57,000              
SIA cash proceeds           $ 140,000                    
Increase in share capital of Cellectis after deduction of transaction costs                 $ 82,800 82,800            
Conversion ratio description                 1 share to 1.06              
Fair value measurement of derivative     $ 48,400                          
Initial fair value amount   $ 57,000         42,700 $ 57,000     42,700          
Gain (loss) on fair value measurement             $ 5,700 $ 14,300                
Gain on change in fair value measurement recognized                 $ 765 $ 20,009 $ 245          
Class A Preferred Shares                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares   10,000,000 10,000,000         10,000,000                
Class B Preferred Shares                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares   18,000,000 18,000,000         18,000,000                
Class A and B Preferred Shares                                
Disclosure of changes in accounting estimates [line items]                                
Share issuance price | $ / shares     $ 5                          
Ordinary shares [member]                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares             71,751,201   72,339,441 72,093,873 71,751,201         45,675,968
Preference shares [member]                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares                 28,000,000 28,000,000            
Conversion ratio description     Both classes of preferred shares benefit from a liquidation preference and are convertible into ordinary shares with the same rights as the outstanding ordinary shares on a one-for-one basis.                          
Conversion ratio     1                          
Astra Zeneca [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Proceeds from sale of ordinary shares         $ 80,000                      
Share issuance price | $ / shares         $ 5                      
Proportion of ownership interest         22.00%                      
Percentage of voting equity interest         21.00%                      
Proceeds from sale of preferred shares     $ 140,000                          
Astra Zeneca [Member] | Ordinary shares [member]                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares         16,000,000                      
Joint Collaboration and Research Agreement [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Collaboration agreement, upfront payment received $ 25,000       $ 25,000                      
Total upfront payments         $ 109,100                      
Joint Collaboration and Research Agreement [Member] | Astra Zeneca [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Initial term for selection of candidate products         5 years                      
Subsequent Investment Agreement (SIA) [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares   28,000,000           28,000,000                
Conversion ratio description   one-for-one basis                            
Initial fair value amount     48,400   $ 48,400                      
Subsequent Investment Agreement (SIA) [Member] | "Class A" Convertible Preferred Shares [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Number of shares issued | shares   10,000,000           10,000,000                
Initial Investment Agreement [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Proceeds from sale of ordinary shares         80,000                      
Reallocated proceeds from sale of ordinary shares         35,700                      
Proceeds reallocated to the JRCA         $ 35,728                      
AZ JRCA, IIA and SIA [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Deferred revenue     $ 84,100                          
Top of Range [member] | Joint Collaboration and Research Agreement [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Milestone Payment 253,000                              
Milestone Payment For 10 Candidate 220,000                              
Top of Range [member] | Joint Collaboration and Research Agreement [Member] | Astra Zeneca [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Number of candidate products for novel cell and gene therapy | Cell         10                      
Bottom of Range [member] | Joint Collaboration and Research Agreement [Member]                                
Disclosure of changes in accounting estimates [line items]                                
Milestone Payment 80,000                              
Milestone Payment For 10 Candidate $ 70,000